Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence

Bone Marrow Transplantation volume 56, pages 2355–2366 (2021)Cite this article

Subjects

Abstract

Temcell is a cryopreserved, human bone marrow-derived mesenchymal stem cell (MSC) product approved for the treatment of patients of all ages with acute graft-versus-host disease (GVHD). Initial experience with Temcell in a real-world setting from a cellular therapy registry in Japan is presented. A total of 381 consecutive patients were enrolled since its approval in 2016. The median cell number infused was 2.00 × 106/kg. The most common number of infusions was 8 in 100 patients. Of the 306 evaluable patients, the overall response rate (ORR) on day 28 after the start of MSC therapy was 56%. Of the 151 evaluable patients who received it as second-line therapy following first-line steroid therapy for classic acute GVHD, the ORR was 61%. Liver involvement of GVHD and ≥14 days from first-line steroid therapy to second-line MSC therapy was associated with a lower ORR. Day 28 ORR, patient age, GVHD grade, GVHD organ involvement, and a number of GVHD therapies before MSC therapy were associated with nonrelapse mortality. Overall survival at 6 months in 381 patients was 40%. This study suggests that Temcell is one of the treatment options for steroid-refractory acute GVHD until a new treatment with survival benefit is developed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Characteristics of MSC therapy.
Fig. 2: ORR of acute GVHD with MSC therapy.
Fig. 3: NRM after MSC therapy.
Fig. 4: OS after MSC therapy.
Fig. 5: OS after MSC therapy in 381 patients.

Similar content being viewed by others

References

  1. Zeiser R, Blazar BR. Acute graft-versus-host disease—biologic process, prevention, and therapy. N. Engl J Med. 2017;377:2167–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transpl. 2015;21:761–7.

    Article  Google Scholar 

  3. Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T, Fukuda T, et al. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2013;19:1183–9.

    Article  CAS  Google Scholar 

  4. Malard F, Huang XJ, Sim JPY. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease. Leukemia .2020;34:1229–40.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726–36.

    Article  CAS  PubMed  Google Scholar 

  6. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet .2004;363:1439–41.

    Article  PubMed  Google Scholar 

  7. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet .2008;371:1579–86.

    Article  PubMed  CAS  Google Scholar 

  8. von Bonin M, Stölzel F, Goedecke A, Richter K, Wuschek N, Hölig K, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transpl. 2009;43:245–51.

    Article  CAS  Google Scholar 

  9. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, et al. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transpl. 2011;17:534–41.

    Article  CAS  Google Scholar 

  10. Ball LM, Bernardo ME, Roelofs H, van Tol MJ, Contoli B, Zwaginga JJ, et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br J Haematol. 2013;163:501–9.

    Article  CAS  PubMed  Google Scholar 

  11. Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transpl. 2014;20:375–81.

    Article  Google Scholar 

  12. Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transpl. 2014;20:1580–5.

    Article  Google Scholar 

  13. Erbey F, Atay D, Akcay A, Ovali E, Ozturk G. Mesenchymal stem cell treatment for steroid refractory graft-versus-host disease in children: a pilot and first study from Turkey. Stem Cells Int. 2016;2016:1641402.

    Article  PubMed  CAS  Google Scholar 

  14. Dotoli GM, De Santis GC, Orellana MD, de Lima Prata K, Caruso SR, Fernandes TR, et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2017;52:859–62.

    Article  CAS  Google Scholar 

  15. Ringden O, Baygan A, Remberger M, Gustafsson B, Winiarski J, Khoein B, et al. Placenta-derived decidua stromal cells for treatment of severe acute graft-versus-host disease. Stem Cells Transl Med. 2018;7:325–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, et al. Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival. Br J Haematol. 2019;185:89–92.

    Article  PubMed  PubMed Central  Google Scholar 

  17. van der Wagen LE, Miranda-Bedate A, Janssen A, Fernando F, Appukudige N, van Dooremalen S, et al. Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile. Bone Marrow Transpl. 2020;55:2188–92.

    Article  CAS  Google Scholar 

  18. Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A, et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res. 2013;3:225–38.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N, et al. Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome. Stem Cells. 2016;34:357–66.

    Article  CAS  Google Scholar 

  20. Salmenniemi U, Itälä-Remes M, Nystedt J, Putkonen M, Niittyvuopio R, Vettenranta K, et al. Good responses but high TRM in adult patients after MSC therapy for GvHD. Bone Marrow Transpl. 2017;52:606–8.

    Article  CAS  Google Scholar 

  21. Kuçi Z, Bönig H, Kreyenberg H, Bunos M, Jauch A, Janssen JW, et al. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica.2016;101:985–94.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Bader P, Kuçi Z, Bakhtiar S, Basu O, Bug G, Dennis M, et al. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM). Bone Marrow Transpl. 2018;53:852–62.

    Article  CAS  Google Scholar 

  23. Bonig H, Kuçi Z, Kuçi S, Bakhtiar S, Basu O, Bug G, et al. Children and adults with refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation “MSC-FFM”-outcome report of 92 patients. Cells .2019;8:1577.

    Article  CAS  PubMed Central  Google Scholar 

  24. Rizk M, Monaghan M, Shorr R, Kekre N, Bredeson CN, Allan DS. Heterogeneity in studies of mesenchymal stromal cells to treat or prevent graft-versus-host disease: a scoping review of the evidence. Biol Blood Marrow Transpl. 2016;22:1416–23.

    Article  Google Scholar 

  25. Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, et al. A phase 3 randomized study of remestemcel-l versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transpl. 2020;26:835–44.

    Article  CAS  Google Scholar 

  26. Kurtzberg J, Prockop S, Chaudhury S, Horn B, Nemecek E, Prasad V, et al. Study 275: updated expanded access program for remestemcel-l in steroid-refractory acute graft-versus-host disease in children. Biol Blood Marrow Transpl. 2020;26:855–64.

    Article  CAS  Google Scholar 

  27. Kurtzberg J, Abdel-Azim H, Carpenter P, Chaudhury S, Horn B, Mahadeo K, et al. A phase 3, single-arm, prospective study of remestemcel-l, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease. Biol Blood Marrow Transpl. 2020;26:845–54.

    Article  CAS  Google Scholar 

  28. Muroi K, Miyamura K, Ohashi K, Murata M, Eto T, Kobayashi N, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study. Int J Hematol. 2013;98:206–13.

    Article  CAS  PubMed  Google Scholar 

  29. Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol. 2016;103:243–50.

    Article  CAS  PubMed  Google Scholar 

  30. Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86:269–74.

    Article  PubMed  Google Scholar 

  31. Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103:3–10.

    Article  PubMed  Google Scholar 

  32. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J. et al. Consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.

    CAS  Google Scholar 

  33. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.

    Article  Google Scholar 

  34. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.

    Article  CAS  PubMed  Google Scholar 

  35. Cox DR. Regression models and life tables. J R Stat Soc [B]. 1972;34:187–220.

    Google Scholar 

  36. Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N. Engl J Med 2020;382:1800–10.

    Article  PubMed  Google Scholar 

  37. Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, et al. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease. Oncologist .2020;25:e328–4.

    Article  CAS  PubMed  Google Scholar 

  38. Socié G, Vigouroux S, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, et al. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood .2017;129:643–9.

    Article  PubMed  CAS  Google Scholar 

  39. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2012;18:1150–63.

    Article  Google Scholar 

  40. García-Cadenas I, Rivera I, Martino R, Esquirol A, Barba P, Novelli S, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow Transpl. 2017;52:107–13.

    Article  CAS  Google Scholar 

  41. Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, et al. Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transpl. 2009;15:777–84.

    Article  CAS  Google Scholar 

  42. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transpl. 2009;15:804–11.

    Article  CAS  Google Scholar 

  43. Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, et al. Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT. Bone Marrow Transpl. 2017;52:252–7.

    Article  CAS  Google Scholar 

  44. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood .2004;104:649–54.

    Article  CAS  PubMed  Google Scholar 

  45. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood .2014;123:3664–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2009;15:367–9.

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the physicians and data managers at each hospital who contributed valuable transplantation data to the Japanese Data Center for Hematopoietic Cell Transplantation.

Funding

This study was supported in part by a Grant-in-Aid for Scientific Research (18K08321 to M.M.) from the Japan Society for the Promotion of Science (JSPS) and a Practical Research Project for Allergic Diseases and Immunology (Research on Technology of Medical Transplantation) (JP20ek0510032 to M.M.) from the Japan Agency for Medical Research and Development (AMED).

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Makoto Murata & Seitaro Terakura

  2. Department of Hematology, Toranomon Hospital Kajigaya, Kanagawa, Japan

    Atsushi Wake

  3. Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan

    Kotaro Miyao

  4. Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan

    Kazuhiro Ikegame

  5. Department of Hematology, Toranomon Hospital, Tokyo, Japan

    Naoyuki Uchida

  6. Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

    Keisuke Kataoka & Shinichiro Okamoto

  7. Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

    Toshihiro Miyamoto

  8. Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan

    Makoto Onizuka

  9. Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan

    Tetsuya Eto

  10. Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan

    Noriko Doki

  11. Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan

    Shuichi Ota

  12. Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, Izumi, Japan

    Maho Sato

  13. Department of Cancer Immunotherapy/Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan

    Yoshiko Hashii

  14. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    Tatsuo Ichinohe

  15. Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan

    Takahiro Fukuda

  16. Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

    Yoshiko Atsuta

  17. Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Yoshiko Atsuta

  18. Department of Hematology, Hokkaido University Graduate School of Medical Science, Sapporo, Japan

    Takanori Teshima

Authors
  1. Makoto Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seitaro Terakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Atsushi Wake
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kotaro Miyao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuhiro Ikegame
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naoyuki Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keisuke Kataoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshihiro Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Makoto Onizuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tetsuya Eto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Noriko Doki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Shuichi Ota
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Maho Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yoshiko Hashii
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tatsuo Ichinohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Takahiro Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Yoshiko Atsuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Shinichiro Okamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Takanori Teshima
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Makoto Murata.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Murata, M., Terakura, S., Wake, A. et al. Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. Bone Marrow Transplant 56, 2355–2366 (2021). https://doi.org/10.1038/s41409-021-01304-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-021-01304-y

This article is cited by

Search

Advanced search

Quick links